Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Advanced BioMedical Technologies's EV-to-FCF or its related term are showing as below:
ABMT'
s EV-to-FCF Range Over the Past 10 Years
Min: -1 Med: 0 Max: 0
Current: -1
ABMT's EV-to-FCF is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 23.015
vs ABMT: -1.00
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Advanced BioMedical Technologies's PE Ratio (TTM) for today is calculated as:
Advanced BioMedical Technologies's share price for today is $0.0005.
Advanced BioMedical Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jul. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.008.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Advanced BioMedical Technologies EV-to-FCF Related Terms
Advanced BioMedical Technologies EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Advanced BioMedical Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced BioMedical Technologies EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced BioMedical Technologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Advanced BioMedical Technologies's EV-to-FCF falls into.
Advanced BioMedical Technologies's current Enterprise Value is $0.04 Mil.
Advanced BioMedical Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Jul. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced BioMedical Technologies (ABMT) has a EV-to-FCF of -1.00 as of Jul. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Advanced BioMedical Technologies and its competitors.
Is Advanced BioMedical Technologies' EV-to-FCF too high?
Advanced BioMedical Technologies' current EV-to-FCF is -1.00.
How does Advanced BioMedical Technologies' EV-to-FCF compare to VYCO and ADMT?
Advanced BioMedical Technologies' EV-to-FCF of -1.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median EV-to-FCF is 23.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.02, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Advanced BioMedical Technologies and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced BioMedical Technologies's current EV-to-FCF is -1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced BioMedical Technologies stock overvalued right now?
Advanced BioMedical Technologies (ABMT) has a current EV-to-FCF of -1.00. The current EV-to-FCF is -1.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Advanced BioMedical Technologies (ABMT), the current EV-to-FCF is -1.00 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advanced BioMedical Technologies Business Description
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable, biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABMT has been successfully added to your 
